Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIV-573 in moderate to severe atopic dermatitis
NCT07782333Phase 2Recruiting
- Sponsor
- Triveni Bio
- Start
- Sep 2026
- Primary completion
- Aug 2027
- Countries
- 3
01
Overview
A Phase 2 trial of TRIV-573 in atopic dermatitis (AD), sponsored by Triveni Bio. Started Sep 2026; status: recruiting.
02
Drugs
TRIV-573
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07782333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07782333.